China Pharmaceuticals and Healthcare Report Q2 2008

Publication Date	May 2008
Publisher	Business Monitor
Product Type	Report
Pages	99
ISBN Number	1748-1821
Product Code	BMI01042

Buy this product or for assistance call +44 20 7060 7474

PDF £425.00$707 | €476

FAX Order above formats by FAX

Summary

China's US$34bn pharmaceutical market is the most attractive in BMI's universe, primarily because of its double-digit growth rate. Over the next 12 months, we are forecasting highly impressive 20% growth, which will taper off over the next five years to reach a still very healthy 15% year-on-year (y-o-y) figure.

By 2012, we are expecting sales of pharmaceuticals - patented medicines, generic drugs and over-thecounter (OTC) medicines - in China to reach US$74.9bn.

In Q208 BMI substantially overhauled its historical data and forecasts for China's trade in pharmaceuticals after confirmed 2007 figures and commentary were released by Chinese Customs Statistics and the China Chamber of Commerce. In 2007, the value of exports increased by 28.2% to US$11.69bn, while imports rose by 32.3% to US$9.37bn, resulting in a positive trade balance of US$5.62bn. Over the next five years, we are expecting both indicators to continue their upward trajectory as internal consumption of foreign medicine increases and demand for Chinese-made drugs grows abroad.

In 2012, we expect the value of exports and imports to reach US$39.66bn and US$30.33bn, respectively.

Conducting clinical trials in China is becoming increasingly popular. However, taking a regional perspective reveals that India is the premier location in Asia Pacific. Demonstrating commitment to its investment, leading US clinical research organisation (CRO) Quintiles Transnational announced in January 2008 that it was expanding its Global Central Laboratories and Clinical Development Services (CDS) units in Beijing to accommodate growing business in China.

In January 2008, BMI upgraded its impression of China's domestic R&D sector after it was announced that a locally-developed vaccine against Helicobacter pylori will be commercialised. The vaccine follows the introduction of the world's first gene therapy by Hubei-based Benda Pharmaceuticals and precedes a possible pandemic-preventing bird flu vaccine from Sinovac Biotech.

In Q108 it was revealed that the number of people suffering ischaemic (blood clot) strokes in China has increased in line with national wealth, according to results from a long-term epidemiological study published in the journal Stroke. However, fewer people are dying from their first stroke, resulting in increased demand for both supportive care and pharmaceuticals to prevent recurrence of the condition.

BMI expects these trends to continue in the medium term as the country's economy matures and population ages.

Content

Executive Summary
China Pharmaceuticals And Healthcare Industry SWOT
China Political SWOT
China Economic SWOT
China Business Environment SWOT
Pharmaceutical Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns
China: Market Summary
Regulatory Regime
Intellectual Property Issues
Counterfeit Activities
Pricing And Reimbursement
Advertising Sector
SFDA Scandal
Other Regulatory Developments
Industry Trends And Developments
Healthcare Sector
Hospital Sector
Epidemiology
Overseas Activity
Domestic Pharmaceutical Sector
Recent Developments In The Local Pharmaceutical Sector
Distribution Sector
Foreign Company Activity
Acquisitions
Traditional Chinese Medicines
Research and Development Activity
Vaccine Sector
Clinical Trials Activity
Biotechnology Sector
Active Pharmaceutical Ingredients (APIs)
Industry Forecast Scenario
Overall Market Forecast
Key Growth Factors - Industry
Key Growth Factors - Macroeconomic
Prescription Market Forecast
OTC Market Forecast
Generics And Patented Market Forecasts
Export/Import Forecasts
Medical Device Market Forecast
China: Medical Device Market Data And Forecasts (US$bn unless otherwise stated)
Other Healthcare Data Forecasts
Key Risks To BMI's Forecast Scenario
Competitive Landscape
Company Profiles
Leading Multinational Companies
GlaxoSmithKline
Pfizer
AstraZeneca
Merck KGaA
Sanofi-Aventis
Novartis
Roche
Merck & Co
Bayer Schering Pharma
Indigenous Manufacturers
North China Pharmaceutical Group Corporation (NCPC)
China Biopharmaceuticals Holdings (CBH)
Hubei Biocause Heilen Pharmaceuticalo
Aida Pharmaceutical Holdings
Shijiazhuang Pharmaceutical (CSPC)
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Weighting
Sources
List of Tables
- Table: Pharmaceutical Business Environment Rankings
- Table: Five-Step Procedure For Drug Pricing In China
- Table: Traditional Chinese Medicine In China
- Table: Major Multinationals With R&D Facilities In China
- Table: China - Drug Market Data And Forecasts
- Table: China - Health Expenditure Data And Forecasts
- Table: China - Economic Activity
- Table: China - Prescription Drug Market Data And Forecasts (US$mn unless otherwise stated)
- Table: China - OTC Market Data And Forecasts (US$mn unless otherwise stated)
- Table: China - Generics And Patented Market Forecasts
- Table: China - Pharmaceutical Trade Data And Forecasts (US$mn
- Table: China - Hospital Data Forecasts
- Table: Competitive Landscape In China
- Table: Top 10 OTC Companies In China By 2006 Sales
- Table: Pharmaceutical Business Environment Indicators
- Table: Weighting Of Components

Delivery Details

PDF:Immediate delivery

Ask a question about this product

Need help finding the right product?

Product features / use

Scope	Expert Insight/Opinion
Level	General Industry Strategies
Data	Detailed Market Forecasts
Profiles	Profiles of Key Companies
Features	Contains SWOT Analysis
Extra Info	Consumer Trends Highlighted